Washington, D.C., Nov. 3, 2021 — As November marks Alzheimer’s Awareness Month, a new review in the American Journal of Psychiatry examines the current state of research on Alzheimer’s disease and potential future directions. Central to the authors’ argument is the unconventional idea that the presence of amyloid and tau are merely biomarkers of the disease, and that treatments focused on them may not improve patient outcomes.
Alzheimer’s disease is a neuropsychiatric disorder affecting more than six million Americans. One in three seniors dies with Alzheimer’s or another dementia according to the Alzheimer’s Association. In “Amyloid and Tau in Alzheimer’s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?” the authors, led by Anand Kumar, M.D., M.H.A., review the clinical and...Read More